Evotec AG announced today that LAB282, the drug discovery BRIDGE between Oxford University, has made its second round of awards to support promising life sciences ideas emerging from the University. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/lab282-accelerates-with-second-round-funding-5472